EVerZom participated in the 19th ECCO (European Crohn's and Colitis Organization) Congress, held in Stockholm in February 2024, and presented its advances to clinicians and experts in the field. Paris ...
Everzom SAS, a CNRS/Université Paris Cité spin-off, has signed a second exclusive license agreement with Erganeo SAS for the development of Evergel, an exosome drug candidate for fistulas and fibrosis ...
Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its exosome biomanufacturing platform to advance ...
This new worldwide license marks a significant step forward in EVerZom's mission to bring innovative exosome-based therapeutic solutions to patients suffering from serious digestive diseases. EVerGel ...
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results